| Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status PG Baverel, VFS Dubois, CY Jin, Y Zheng, X Song, X Jin, ... Clinical Pharmacology & Therapeutics 103 (4), 631-642, 2018 | 133 | 2018 |
| Identifying the translational gap in the evaluation of drug‐induced QTc interval prolongation ASY Chain, VFS Dubois, M Danhof, MCJM Sturkenboom, O Della Pasqua, ... British journal of clinical pharmacology 76 (5), 708-724, 2013 | 38 | 2013 |
| Assessment of interspecies differences in drug-induced QTc interval prolongation in cynomolgus monkeys, dogs and humans VFS Dubois, WEA De Witte, SAG Visser, M Danhof, O Della Pasqua Pharmaceutical research 33 (1), 40-51, 2016 | 25 | 2016 |
| 19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions O Hamid, M Hellman, B Carneiro, T Marron, V Subbiah, I Mehmi, J Eyles, ... Annals of Oncology 32, S9, 2021 | 17 | 2021 |
| Translating QT interval prolongation from conscious dogs to humans VFS Dubois, G Smania, H Yu, R Graf, ASY Chain, M Danhof, ... British journal of clinical pharmacology 83 (2), 349-362, 2017 | 13 | 2017 |
| Model‐based evaluation of drug‐induced QT c prolongation for compounds in early development VFS Dubois, H Yu, M Danhof, O Della Pasqua, ... British journal of clinical pharmacology 79 (1), 148-161, 2015 | 11 | 2015 |
| Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors. P Baverel, V Dubois, C Jin, X Song, X Jin, P Mukhopadhyay, AK Gupta, ... Journal of Clinical Oncology 35 (15_suppl), 2566-2566, 2017 | 9 | 2017 |
| Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models VT Truong, PG Baverel, GD Lythe, P Vicini, JWT Yates, VFS Dubois CPT: pharmacometrics & systems pharmacology 11 (2), 133-148, 2022 | 8 | 2022 |
| Pharmacokinetic–pharmacodynamic modelling of drug‐induced QTc interval prolongation in man: prediction from in vitro human ether‐à‐go‐go‐related gene … VFS Dubois, E Casarotto, M Danhof, O Della Pasqua British journal of pharmacology 173 (19), 2819-2832, 2016 | 8 | 2016 |
| Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results AL Vavere, M Sinsakul, EL Ongstad, Y Yang, V Varma, C Jones, ... Journal of the American Heart Association 12 (3), e027540, 2023 | 7 | 2023 |
| Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy I González‐García, V Pierre, VFS Dubois, N Morsli, S Spencer, ... CPT: pharmacometrics & systems pharmacology 10 (3), 230-240, 2021 | 7 | 2021 |
| Concentration‐QT modelling in early clinical oncology settings: simulation evaluation of performance G Cantet, A Berges, R O'Sullivan, S Cohen‐Rabbie, C Dota, V Dubois, ... British Journal of Clinical Pharmacology 88 (3), 1010-1019, 2022 | 5 | 2022 |
| Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total J Hood, I González-García, N White, L Marshall, VFS Dubois, P Vicini, ... Pharmaceutics 13 (4), 519, 2021 | 2 | 2021 |
| The safety and efficacy of single and multiple ascending doses of MEDI6570 in participants with type 2 diabetes mellitus AL Vavere, M Sinsakul, E Ongstad, Y Yang, V Varma, V Dubois, ... Journal of the American College of Cardiology 77 (18_Supplement_1), 1189-1189, 2021 | 1 | 2021 |
| PKPD modelling of drug-induced QTc interval prolongation in man: prediction from in vitro hERG binding and functional inhibition assays and conscious dog studies VFS Dubois, E Casarotto, M Danhof, OE Della Pasqua Br J Pharmacol 173, 2819-2832, 2016 | 1 | 2016 |
| Stochastic pharmacodynamics of a heterogeneous tumour-cell population VT Truong, P Vicini, J Yates, V Dubois, G Lythe | | 2024 |
| Stochastic pharmacodynamics of a heterogeneous tumour-cell population P Vicini, J Yates, V Dubois, G Lythe | | 2024 |
| A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy J Yates, P Vicini, V Dubois, G Lythe | | 2024 |
| A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy VT Truong, J Yates, P Vicini, V Dubois, G Lythe | | 2024 |
| CLINICAL TRIAL SIMULATIONS SHOW GOOD PERFORMANCE OF THE CONCENTRATION-QT MODEL IN CLINICAL ONCOLOGY SETTINGS. G Cantet, A Berges, S Cohen-Rabbie, D RekiA, J Parkinson, C Dota, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S8-S8, 2021 | | 2021 |
